These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21732248)

  • 61. A Fragment-Based Ligand Screen Against Part of a Large Protein Machine: The ND1 Domains of the AAA+ ATPase p97/VCP.
    Chimenti MS; Bulfer SL; Neitz RJ; Renslo AR; Jacobson MP; James TL; Arkin MR; Kelly MJ
    J Biomol Screen; 2015 Jul; 20(6):788-800. PubMed ID: 25690569
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of a Novel Inhibitory Allosteric Site in p38α.
    Gomez-Gutierrez P; Campos PM; Vega M; Perez JJ
    PLoS One; 2016; 11(11):e0167379. PubMed ID: 27898710
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Creating a more strategic small molecule biophysical hit characterization workflow.
    Fotsch C; Basu D; Case R; Chen Q; Koneru PC; Lo MC; Ngo R; Sharma P; Vaish A; Yi X; Zech SG; Hodder P
    SLAS Discov; 2024 Jun; 29(4):100159. PubMed ID: 38723666
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Crystallographic analysis of TPP riboswitch binding by small-molecule ligands discovered through fragment-based drug discovery approaches.
    Warner KD; Ferré-D'Amaré AR
    Methods Enzymol; 2014; 549():221-33. PubMed ID: 25432751
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification of Novel Fragments Binding to the PDZ1-2 Domain of PSD-95.
    Zang J; Ye F; Solbak SMØ; Høj LJ; Zhang M; Bach A
    ChemMedChem; 2021 Mar; 16(6):949-954. PubMed ID: 33305877
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The SeeDs approach: integrating fragments into drug discovery.
    Hubbard RE; Davis B; Chen I; Drysdale MJ
    Curr Top Med Chem; 2007; 7(16):1568-81. PubMed ID: 17979768
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Increasing chemical space coverage by combining empirical and computational fragment screens.
    Barelier S; Eidam O; Fish I; Hollander J; Figaroa F; Nachane R; Irwin JJ; Shoichet BK; Siegal G
    ACS Chem Biol; 2014 Jul; 9(7):1528-35. PubMed ID: 24807704
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Binding-site assessment by virtual fragment screening.
    Huang N; Jacobson MP
    PLoS One; 2010 Apr; 5(4):e10109. PubMed ID: 20404926
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fragment-based lead discovery and design.
    Joseph-McCarthy D; Campbell AJ; Kern G; Moustakas D
    J Chem Inf Model; 2014 Mar; 54(3):693-704. PubMed ID: 24490951
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
    Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
    Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor.
    Chen D; Ranganathan A; IJzerman AP; Siegal G; Carlsson J
    J Chem Inf Model; 2013 Oct; 53(10):2701-14. PubMed ID: 23971943
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Fragment Hits: What do They Look Like and How do They Bind?
    Giordanetto F; Jin C; Willmore L; Feher M; Shaw DE
    J Med Chem; 2019 Apr; 62(7):3381-3394. PubMed ID: 30875465
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
    Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
    Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
    [TBL] [Abstract][Full Text] [Related]  

  • 74. One Question, Multiple Answers: Biochemical and Biophysical Screening Methods Retrieve Deviating Fragment Hit Lists.
    Schiebel J; Radeva N; Köster H; Metz A; Krotzky T; Kuhnert M; Diederich WE; Heine A; Neumann L; Atmanene C; Roecklin D; Vivat-Hannah V; Renaud JP; Meinecke R; Schlinck N; Sitte A; Popp F; Zeeb M; Klebe G
    ChemMedChem; 2015 Sep; 10(9):1511-21. PubMed ID: 26259992
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Fluorophore labeled kinase detects ligands that bind within the MAPK insert of p38α kinase.
    Getlik M; Simard JR; Termathe M; Grütter C; Rabiller M; van Otterlo WA; Rauh D
    PLoS One; 2012; 7(7):e39713. PubMed ID: 22768308
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002.
    Parker LJ; Taruya S; Tsuganezawa K; Ogawa N; Mikuni J; Honda K; Tomabechi Y; Handa N; Shirouzu M; Yokoyama S; Tanaka A
    Acta Crystallogr D Biol Crystallogr; 2014 Feb; 70(Pt 2):392-404. PubMed ID: 24531473
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Multiplexed experimental strategies for fragment library screening against challenging drug targets using SPR biosensors.
    FitzGerald EA; Vagrys D; Opassi G; Klein HF; Hamilton DJ; Talibov VO; Abramsson M; Moberg A; Lindgren MT; Holmgren C; Davis B; O'Brien P; Wijtmans M; Hubbard RE; de Esch IJP; Danielson UH
    SLAS Discov; 2024 Jan; 29(1):40-51. PubMed ID: 37714432
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Lead generation and examples opinion regarding how to follow up hits.
    Orita M; Ohno K; Warizaya M; Amano Y; Niimi T
    Methods Enzymol; 2011; 493():383-419. PubMed ID: 21371599
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
    Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
    J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.